Three FDA Guidances: Using Real-World Data in Observational Studies and DSCSA

The FDA issued three final guidances on Wednesday, one on the use of real-world data (RWD) in noninterventional (observational) studies and two on the Drug Supply Chain Security Act (DSCSA).
Source: Drug Industry Daily

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.